Related references
Note: Only part of the references are listed.Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes
Christoph Mueller et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2021)
The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases
Jeffrey Cummings
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2021)
Pattern of treatment of behavioural and psychological symptoms of dementia and pain: evidence on pharmacoutilization from a large real-world sample and from a centre for cognitive disturbances and dementia
Damiana Scuteri et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Late-life depression and increased risk of dementia: a longitudinal cohort study
M. Ly et al.
TRANSLATIONAL PSYCHIATRY (2021)
Will psychedelics be ‘a revolution in psychiatry’?
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2021)
Trial of Psilocybin versus Escitalopram for Depression
Robin Carhart-Harris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review
Emma Kopra et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2021)
Inflammatory signaling mechanisms in bipolar disorder
Gregory H. Jones et al.
JOURNAL OF BIOMEDICAL SCIENCE (2021)
Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials
George T. Grossberg et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2020)
Benefits and Harms of Prescription Drugs and Supplements for Treatment of Clinical Alzheimer-Type Dementia A Systematic Review and Meta-analysis
Howard A. Fink et al.
ANNALS OF INTERNAL MEDICINE (2020)
Neuroimmune Connections in Aging and Neurodegenerative Diseases
Hannah Scheiblich et al.
TRENDS IN IMMUNOLOGY (2020)
The cholinergic system in subtypes of Alzheimer's disease: an in vivo longitudinal MRI study
Alejandra Machado et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Pathways Connecting Late-Life Depression and Dementia
Christoph Linnemann et al.
FRONTIERS IN PHARMACOLOGY (2020)
The Use of Risperidone in Behavioral and Psychological Symptoms of Dementia: A Review of Pharmacology, Clinical Evidence, Regulatory Approvals, and Off-Label Use
Ismaeel Yunusa et al.
FRONTIERS IN PHARMACOLOGY (2020)
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Gill Livingston et al.
LANCET (2020)
Drug repositioning and repurposing for Alzheimer disease
Clive Ballard et al.
NATURE REVIEWS NEUROLOGY (2020)
Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers-results from the DELCODE study
Lena Sannemann et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Network Simulations Reveal Molecular Signatures of Vulnerability to Age-Dependent Stress and Tau Accumulation
Timothy E. Hoffman et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2020)
Systemic inflammation impairs microglial Aβ clearance through NLRP3 inflammasome
Dario Tejera et al.
EMBO JOURNAL (2019)
Mechanisms and treatment of late-life depression
George S. Alexopoulos
TRANSLATIONAL PSYCHIATRY (2019)
Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer's disease and their correlation with cognitive decline
Ricardo Taipa et al.
NEUROBIOLOGY OF AGING (2019)
Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia A Network Meta-analysis
Ismaeel Yunusa et al.
JAMA NETWORK OPEN (2019)
Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study
Clive Ballard et al.
LANCET NEUROLOGY (2018)
Evidence for accuracy of pain assessment and painkillers utilization in neuropsychiatric symptoms of dementia in Calabria region, Italy
Damiana Scuteri et al.
NEURAL REGENERATION RESEARCH (2018)
Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders
Ebrahim Haroon et al.
NEUROPSYCHOPHARMACOLOGY (2017)
The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre- Dementia Populations
Zahinoor Ismail et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Trajectories of Depressive Symptoms Before Diagnosis of Dementia A 28-Year Follow-up Study
Archana Singh-Manoux et al.
JAMA PSYCHIATRY (2017)
Prophylactic versus Therapeutic Fingolimod: Restoration of Presynaptic Defects in Mice Suffering from Experimental Autoimmune Encephalomyelitis
Tommaso Bonfiglio et al.
PLOS ONE (2017)
The need for better access to pain treatment: learning from drug consumption trends in the USA
Damiana Scuteri et al.
FUNCTIONAL NEUROLOGY (2017)
Stress-Induced Depressive Behaviors Require a Functional NLRP3 Inflammasome
Elisabet Alcocer-Gomez et al.
MOLECULAR NEUROBIOLOGY (2016)
Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study
Anne K. Leonpacher et al.
AMERICAN JOURNAL OF PSYCHIATRY (2016)
Investigational drugs for treating agitation in persons with dementia
Ricardo P. Garay et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease
Jeffery Newell et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2016)
Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia A Randomized Clinical Trial
Jeffrey L. Cummings et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Regulation of Extrasynaptic Glutamate Levels as a Pathophysiological Mechanism in Disorders of Motivation and Addiction
Robert E. McCullumsmith et al.
NEUROPSYCHOPHARMACOLOGY (2015)
Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
Anton P. Porsteinsson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Changes in QTc Interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) Randomized Trial
Lea T. Drye et al.
PLOS ONE (2014)
Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study
Yoram Barak et al.
INTERNATIONAL PSYCHOGERIATRICS (2011)
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Anita E. Autry et al.
NATURE (2011)
Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression
Rebecca B. Price et al.
BIOLOGICAL PSYCHIATRY (2009)
Aging exacerbates depressive-like behavior in mice in response to activation of the peripheral innate immune system
Jonathan P. Godbout et al.
NEUROPSYCHOPHARMACOLOGY (2008)
A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia
Bruce G. Pollock et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2007)
Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment
Jeffrey L. Cummings et al.
NEUROLOGY (2006)
Lipopolysaccharide-induced microglial activation induces learning and memory deficits without neuronal cell death in rats
S Tanaka et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2006)
Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients
BG Pollock et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Share Paper
